Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunoprecise Antibodies Ltd IPA

Technology Scientific & Technical Instruments
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from the United... see more

Recent & Breaking News (NDAQ:IPA)

ImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

Business Wire March 15, 2023

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023

Business Wire March 7, 2023

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023

Business Wire December 15, 2022

IPA's Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs(TM) and Accelerates in Silico Drug Discovery Developments

Business Wire December 8, 2022

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022

Business Wire December 5, 2022

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

Business Wire November 30, 2022

ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange

Business Wire November 22, 2022

IPA's Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

Business Wire October 12, 2022

NIAID Confirms IPA's PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75

Business Wire September 14, 2022

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023

Business Wire September 14, 2022

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022

Business Wire September 8, 2022

Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope's Efficacy Against SARS-CoV-2 Variants Including BA.5

Business Wire August 29, 2022

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022

Business Wire July 29, 2022

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022

Business Wire July 26, 2022

Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA's PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2

Business Wire July 12, 2022

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

Business Wire May 9, 2022

IPA's Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern

Business Wire April 20, 2022

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

Business Wire April 14, 2022

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

Business Wire March 29, 2022

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022

Business Wire March 16, 2022